A tumor-permeable peptide iRGD by LifeTein targets peritoneal carinomatosis

A tumor-penetrating peptide, iRGD, was synthesized by LifeTein. It was found that iRGD improves tumor-specific penetration of intraperitoneal compounds and enhances intraperitoneal chemotherapy (IPC) in mice. This penetration was tumor-specific. When the fluorescein was attached to iRGD and mixed with nanoparticles, the mixture could penetrate into fresh human peritoneal metastasis explants. The evidence proved that the LifeTein iRGD enhanced intratumoral entry. The intraperitoneal iRGD co-administration is a simple and effective strategy to facilitate tumor detection and potential application for the therapeutic improvement.

LifeTein’s Peptide: iRGD

A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis, Journal of Controlled Release, Volume 212, 28 August 2015, Pages 59–69

Peptide Synthesis Home Page

Our Services:

COVID-19 Services & Products

Custom Antibody Services

Rush Peptide Synthesis

Peptide Nucleic Acids (PNAs)

Custom Peptide Synthesis Services

Gene Synthesis Service

Custom Chemical Synthesis

Other Posts:

Nanoparticles Get Help from Cell-Permeable Peptides

Predicting type 1 diabetes in children

Improving Antibody Therapy For Colorectal Cancer

To Make Simpler and Better Biosensors

A New Patent Using Peptides